Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
AffiliationDepartment of Medical Oncology , Santa Maria della Misericordia Hospital , Perugia , Italy
MetadataShow full item record
AbstractSmall cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic treatments and the established management paradigm of platinum-based chemotherapy has reached an efficacy plateau. Several clinical trials have investigated targeted therapies, without producing clinically significant benefits. Recently presented early phase clinical trials with immune checkpoint inhibitors (blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and blockade of the programmed cell death-1 (PD-1) receptor) have shown promising results. In this review, we present the emerging evidence on immune checkpoint blockade for SCLC.
CitationImmune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? 2016, 1(4):e000022 ESMO Open
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
- Authors: Mahoney KM, Freeman GJ, McDermott DF
- Issue date: 2015 Apr 1
- The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
- Authors: Horn L, Reck M, Spigel DR
- Issue date: 2016 Aug
- The next generation of immunotherapy: keeping lung cancer in check.
- Authors: Somasundaram A, Burns TF
- Issue date: 2017 Apr 24
- PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
- Authors: Tanvetyanon T, Gray JE, Antonia SJ
- Issue date: 2017 Mar
- Immune checkpoint inhibitors in small cell lung cancer.
- Authors: Pakkala S, Owonikoko TK
- Issue date: 2018 Feb